Literature DB >> 19524782

Parkinson's disease.

Andrew J Lees1, John Hardy, Tamas Revesz.   

Abstract

Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated alpha-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age. Susceptibility genes including alpha-synuclein, leucine rich repeat kinase 2 (LRRK-2), and glucocerebrosidase (GBA) have shown that genetic predisposition is another important causal factor. Dopamine replacement therapy considerably reduces motor handicap, and effective treatment of associated depression, pain, constipation, and nocturnal difficulties can improve quality of life. Embryonic stem cells and gene therapy are promising research therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524782     DOI: 10.1016/S0140-6736(09)60492-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  676 in total

1.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

2.  Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors:  Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2011-04-14       Impact factor: 4.294

3.  Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC.

Authors:  Arjan Kortholt; Wouter N van Egmond; Katarzyna Plak; Leonard Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2011-11-26       Impact factor: 5.157

Review 4.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

5.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

Review 6.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

7.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

9.  A Fuzzy Inference System for Closed-Loop Deep Brain Stimulation in Parkinson's Disease.

Authors:  Carmen Camara; Kevin Warwick; Ricardo Bruña; Tipu Aziz; Francisco del Pozo; Fernando Maestú
Journal:  J Med Syst       Date:  2015-09-18       Impact factor: 4.460

Review 10.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.